Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
LTS-101 is a one-time AAV gene therapy candidate intended to provide durable expression of the TPP1 enzyme in the central…